Prima BioMed (NASDAQ:IMMP) Shares Down 4.2% – Should You Sell?

Posted by Tristan Rich on Oct 1st, 2026

Prima BioMed Ltd (NASDAQ:IMMP – Get Free Report)’s share price dropped 4.2% during trading on Tuesday. The stock traded as low as $4.66 and last traded at $4.6760. Approximately 14,465 shares were traded during mid-day trading, a decline of 94% from the average daily volume of 258,731 shares. The stock had previously closed at $4.88.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on IMMP shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Prima BioMed in a research note on Friday, July 10th. Jefferies Financial Group upgraded shares of Prima BioMed from a “hold” rating to a “strong-buy” rating in a research report on Monday, September 14th. Finally, Maxim Group upgraded Prima BioMed from a “hold” rating to a “buy” rating in a research report on Wednesday, June 17th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Prima BioMed presently has a consensus rating of “Hold” and a consensus target price of $110.00.

Check Out Our Latest Research Report on Prima BioMed

Prima BioMed Price Performance

The business’s 50 day moving average is $7.09 and its 200 day moving average is $8.01.

Prima BioMed (NASDAQ:IMMP – Get Free Report) last announced its earnings results on Thursday, July 30th. The biotechnology company reported ($1.80) earnings per share (EPS) for the quarter. The business had revenue of $3.68 million for the quarter.

Prima BioMed Company Profile

(Get Free Report)

Prima BioMed Limited was an Australian biotechnology company focused on developing novel immunotherapies for cancer and other serious diseases. The company’s research centered on treatments designed to activate or enhance the immune system’s ability to recognize and attack abnormal cells.

Its lead development program was eftilagimod alpha, also known as IMP321, a soluble LAG-3 protein intended to stimulate antigen-presenting cells and support broader immune responses. Prima BioMed evaluated the therapy in combination with existing cancer treatments, including chemotherapy and immune checkpoint inhibitors, across several solid-tumor indications.

The company conducted clinical-development activities internationally, including in Australia, Europe and the United States.